Abstract 477P
Background
Lower grade gliomas (LGGs) represent 15% of all primary brain tumors, and have variable prognosis. The prognostic influence of the ENHO gene in LGGs remains elusive, necessitating further bioinformatic exploration to improve patient management and outcomes.
Methods
Differential gene expression based on High/low ENHO expression was extracted using the “DESeq2” R package. Immune infiltration, mutational burden, gene set variation analysis (GSVA) and drug resistance were analyzed through GSCALite and cBioPortal. Additional immune infiltration and survival analysis used TIMER2.0. Gene set enrichment analysis (GSEA) was conducted via TCGAbiolinks and enriched further using Enrichr.
Results
Multivariate overall survival (OS) analysis showed a protective effect for ENHO (HR = 0.58, p <0.001). GSVA for OS and progression-free survival (PFS) for co-expressed genes and upregulated genes also showcased favorable prognosis OS:(HR = 0.40, p<0.001) and (HR = 0.34, p<0.001), respectively; PFS: (HR = 0.53, p<0.001) and (HR = 0.44, p<0.001), respectively. Survival GSVA of downregulated genes revealed an association with worse OS (HR = 4.19, p < 0.001) and PFS (HR = 2.45, p< 0.001). GSVA for upregulated genes showed a negative correlation with DNA damage, EMT, and PI3KAKT pathways. GSVA for downregulated genes had a positive correlation with EMT, DNA damage, and PI3K/AKT pathways. GSVA for co-expressed genes revealed significant negative correlations with DNA damage and EMT pathways. Mutational burden analysis revealed that shallow deletion is the most common ENHO mutation among all LGG subtypes, regardless of stage. Immune infiltration analysis for ENHO, upregulated, and co-expressed genes showcased the infiltration of: Central memory B cells, CD8 T cells, Neutrophils, and CD4 T cells. Decreased infiltration of cancer associated fibroblasts was observed for high ENHO expression. GSEA of coexpressed genes revealed significant involvement in cell cycle processes and regulation.
Conclusions
ENHO's role in LGG is yet to be determined, but our results showcase a possible protective effect through its modulation of the immune system, cell cycle signalling, and EMT pathways. Primary studies are still needed to validate ENHO's role in LGG.
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
479P - The candidate novel markers PIV and PILE score to predict survival outcomes and therapeutic response in patients with primary central nervous system lymphoma
Presenter: Ling Duan
Session: Poster session 16
Resources:
Abstract
480P - Clinical utility of ctDNA detection by NGS for diagnosis of CNS lymphoma
Presenter: Ana Jiménez-Ubieto
Session: Poster session 16
481P - Integrating GWAS and transcriptomics prioritizes drug targets for meningioma
Presenter: Wan-Zhe Liao
Session: Poster session 16
482P - The prognostic impact of CDKN2A/B heterozygous deletions in meningioma: Insights of a multicenter analysis
Presenter: Franziska Ippen
Session: Poster session 16
483P - The use of steroids associated with PD1/PDL-1 blockage in patients with brain metastasis: A systematic review and meta-analysis
Presenter: Francisco Cezar Moraes
Session: Poster session 16
484P - EGFR amplification is the potential driver gene that accelerates brain metastases in NSCLC patients
Presenter: Hainan Yang
Session: Poster session 16
485P - A spatio-temporal evolution mathematical model of glioma growth: The influence of cellular and nutrient interactions on the tumor microenvironment
Presenter: Kalysta Borges
Session: Poster session 16
486P - Effects of a BBB-penetrating oligonucleotide drug, RBD8088, in mouse models of human glioblastoma
Presenter: Julia Grönros
Session: Poster session 16
487P - 3D-bioprinted co-cultures of glioblastoma and mesenchymal cells indicate a role for perivascular niche cells in shaping the chemotactic tumour microenvironment
Presenter: Radosław Zagożdżon
Session: Poster session 16
488P - ITGA2 promotes glioma cell stemness and progression by activating the AKT pathway
Presenter: Lihui Wang
Session: Poster session 16